Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)
November 03, 2023 08:30 ET
|
Coherus BioSciences, Inc.
– Data demonstrate distinct IL-27-mediated expression of genes associated with immune suppression in vitro, supporting ongoing clinical development of first-in-class anti-IL-27 antibody casdozokitug –...
Coherus BioSciences to Participate at Upcoming November Investor Conferences
November 02, 2023 20:00 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor...
Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023
October 30, 2023 18:00 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that its third quarter 2023 financial results will be released after...
Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
October 27, 2023 15:07 ET
|
Coherus BioSciences, Inc.
– LOQTORZI is the first and only FDA-approved treatment for NPC – – Indicated in combination with chemotherapy for 1st line treatment and as monotherapy for patients with disease progression on or...
Coherus BioSciences Announces New Employment Inducement Grants
October 24, 2023 19:41 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective October 20, 2023, the compensation...
Coherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 14, 2023 12:30 ET
|
Coherus BioSciences, Inc.
— Data demonstrate preclinical potent T cell activation and differentiated mechanism of action and enhanced clinical efficacy irrespective of PD-L1 status when administered in combination with...
Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™
October 05, 2023 08:30 ET
|
Coherus BioSciences, Inc.
– Resubmission follows the satisfactory resolution of the FDA’s review of inspection findings at the third-party filler – REDWOOD CITY, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Coherus...
CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch
October 04, 2023 08:30 ET
|
Coherus BioSciences, Inc.
– CIMERLI® is the #1 ranibizumab biosimilar with 25% ranibizumab market share* – – Demonstrated safety and efficacy in clinical trials and real-world settings – – Robust and reliable supply...
Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day
October 02, 2023 09:00 ET
|
Coherus BioSciences, Inc.
- Bipartisan resolution highlights the challenges patients with rare cancers face and raises awareness and supports efforts to improve early diagnosis and development of effective treatments - - Many...
Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
September 27, 2023 09:10 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced the presentation of three abstracts from its innovative immuno-oncology...